Latest Breaking News On - Greement immu se0005003654 - Page 1 : comparemela.com

TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced an agreement to. | October 18, 2022

Mario brkuljErik mantingLeopold berteaCorey davisLifesci advisorsEuropean society of gynecological oncologyValency communicationsMinaris regenerative medicine gmbhAcute myeloid leukemiaChief technology officerEuropean societyGynecological oncologySci advisorsMendus ab publ stock exchangePress releaseGreement immu se0005003654